Vaccination and Mortality of Patients with a Novel Coronavirus Infection (COVID-19): A Global Approach

Aim. The aim is to study the correlation between the vaccination rate (VR) and mortality rate of patients with COVID-19 (MpCOV).

Methods. The countries with gross domestic product per capita corrected for purchasing power parity (GDP PPP) over $-10,000 were selected for an ecologic study. The city-states and countries with a population of 1,000,000 were excluded. The number of patients who died from COVID-19 within a week was divided by the number of patients diagnosed with COVID-19 within a week 20 days earlier to calculate MpCOV.

Results. We included 85 countries. VR (r = –0.604; p < 0.001) and GDPpcPPP level (p = 0.202), is an independent determinant of MpCOV. There was no significant difference in MpCOV between groups of countries with VR < 20 % and 20–39 % (1.96 [1.21; 4.67] vs. 1.96 [1.01; 3.36] %; p = 0.464). MpCOV was higher in countries where VR were lower when groups of countries with VR of 20–39 %, 40–59 %, 60–79 %, and ≥80 % were compared (1.96 [1.01; 3.36] vs. 1.11 [0.76; 1.64] vs. 0.50 [0.39; 1.00] vs. 0.16 [0.10; 0.21]; p = 0.003; p = 0.020, and p = 0.008).

Conclusions. An increase in VR correlates with a decrease in MpCOV.

1. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. DOI: 10,1016/S0140-6736(21)00234-8

2. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15. DOI: 10,1056/NEJMoa2034577

3. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16. DOI: 10,1056/NEJMoa2035389

4. Cohn B.A., Cirillo P.M., Murphy C.C., Krigbaum N.Y., Wallace A.W. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science. 2021:eabm0620. DOI: 10,1126/science.abm0620

5. Maslennikov R., Ivashkin V., Vasilieva E., Chipurik M., Semikova P., Semenets V., et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol Ther. 2021;69:102039. DOI: 10,1016/j.pupt.2021.102039

6. Maslennikov R., Ivashkin V., Vasilieva E., Chipurik M., Semikova P., Semenets V., et al. Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19). Eur Cytokine Netw. 2021;32(1):8–14. DOI: 10,1684/ecn.2021.0463

7. Tregoning J.S., Flight K.E., Higham S.L., Wang Z., Pierce B.F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–36. DOI: 10,1038/s41577-021-00592-1

8. Cevik M., Grubaugh N.D., Iwasaki A., Openshaw P. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. Cell. 2021;184(20):5077–81. DOI: 10,1016/j.cell.2021.09.010

9. Lopez Bernal J., Andrews N., Gower C., Gallagher E., Simmons R., Thelwall S., et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585–94. DOI: 10,1056/NEJMoa2108891

10. Montgomery J., Ryan M., Engler R., Hoffman D., McClenathan B., Collins L., et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021;6(10):1202–6. DOI: 10,1001/jamacardio.2021.2833

11. Bozkurt B., Kamat I., Hotez P.J. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471–84. DOI: 10,1161/CIRCULATIONAHA.121.056135

12. Abu Mouch S., Roguin A., Hellou E., Ishai A., Shoshan U., Mahamid L., et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021;39(29):3790–3. DOI: 10,1016/j.vaccine.2021.05.087

13. Cines D.B., Bussel J.B. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med. 2021;384(23):2254–6. DOI: 10,1056/NEJMe2106315

14. Lai C.C., Ko W.C., Chen C.J., Chen P.Y., Huang Y.C., Lee P.I., Hsueh P.R. COVID-19 vaccines and thrombosis with thrombocytopenia syndrome. Expert Rev Vaccines. 2021;20(8):1027–35. DOI: 10,1080/14760584.2021.1949294

15. Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;384(22):2092–101. DOI: 10,1056/NEJMoa2104840